[go: up one dir, main page]

WO1997033909A3 - Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer - Google Patents

Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer Download PDF

Info

Publication number
WO1997033909A3
WO1997033909A3 PCT/US1997/004192 US9704192W WO9733909A3 WO 1997033909 A3 WO1997033909 A3 WO 1997033909A3 US 9704192 W US9704192 W US 9704192W WO 9733909 A3 WO9733909 A3 WO 9733909A3
Authority
WO
WIPO (PCT)
Prior art keywords
prostate cancer
polypeptides
compounds
immunotherapy
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1997/004192
Other languages
French (fr)
Other versions
WO1997033909A2 (en
WO1997033909A9 (en
Inventor
Steven G Reed
Davin C Dillon
Daniel R Twardzik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corixa Corp
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp filed Critical Corixa Corp
Priority to NZ331866A priority Critical patent/NZ331866A/en
Priority to AU23295/97A priority patent/AU728186B2/en
Priority to BR9708082A priority patent/BR9708082A/en
Priority to EP97916017A priority patent/EP0914335A2/en
Publication of WO1997033909A2 publication Critical patent/WO1997033909A2/en
Publication of WO1997033909A9 publication Critical patent/WO1997033909A9/en
Publication of WO1997033909A3 publication Critical patent/WO1997033909A3/en
Priority to NO984229A priority patent/NO984229L/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)

Abstract

Compounds and methods for treating and diagnosing prostate cancer are provided. The inventive compounds include polypeptides containing at least a portion of a prostate protein. Vaccines and pharmaceutical compositions for immunotherapy of prostate cancer comprising such polypeptides or DNA molecules encoding such polypeptides are also provided. The inventive polypeptides may also be used to generate antibodies useful for the diagnosis and monitoring of prostate cancer. Nucleic acid sequences for preparing probes, primers, and polypeptides are also provided.
PCT/US1997/004192 1996-03-15 1997-03-14 Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer Ceased WO1997033909A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
NZ331866A NZ331866A (en) 1996-03-15 1997-03-14 Compounds for immunotherapy and immunodiagnosis of prostate cancer
AU23295/97A AU728186B2 (en) 1996-03-15 1997-03-14 Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer
BR9708082A BR9708082A (en) 1996-03-15 1997-03-14 Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer
EP97916017A EP0914335A2 (en) 1996-03-15 1997-03-14 Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer
NO984229A NO984229L (en) 1996-03-15 1998-09-14 Compounds and Methods for Immunotherapy and Immunodiagnosis of Prostate Cancer

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US61674596A 1996-03-15 1996-03-15
US08/616,745 1996-03-15
US63384096A 1996-04-11 1996-04-11
US08/633,840 1996-04-11

Publications (3)

Publication Number Publication Date
WO1997033909A2 WO1997033909A2 (en) 1997-09-18
WO1997033909A9 WO1997033909A9 (en) 1997-11-27
WO1997033909A3 true WO1997033909A3 (en) 1997-12-24

Family

ID=27087847

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/004192 Ceased WO1997033909A2 (en) 1996-03-15 1997-03-14 Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer

Country Status (11)

Country Link
US (1) US6034218A (en)
EP (1) EP0914335A2 (en)
KR (1) KR19990087802A (en)
AR (1) AR006250A1 (en)
AU (1) AU728186B2 (en)
BR (1) BR9708082A (en)
CA (1) CA2249742A1 (en)
CO (1) CO4600637A1 (en)
NO (1) NO984229L (en)
NZ (1) NZ331866A (en)
WO (1) WO1997033909A2 (en)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6592877B1 (en) * 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6290969B1 (en) * 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
SE520392C2 (en) 1996-09-27 2003-07-01 Creative Peptides Sweden Ab C Specific peptides for the treatment of diabetes mellitus
US6630305B1 (en) 1999-11-12 2003-10-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6800746B2 (en) 1997-02-25 2004-10-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6329505B1 (en) 1997-02-25 2001-12-11 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
US6613872B1 (en) 1997-02-25 2003-09-02 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US6894146B1 (en) 1997-02-25 2005-05-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7517952B1 (en) 1997-02-25 2009-04-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7033827B2 (en) 1997-02-25 2006-04-25 Corixa Corporation Prostate-specific polynucleotide compositions
US6620922B1 (en) 1997-02-25 2003-09-16 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6261562B1 (en) 1997-02-25 2001-07-17 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US20030185830A1 (en) 1997-02-25 2003-10-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6759515B1 (en) 1997-02-25 2004-07-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6395278B1 (en) 1997-02-25 2002-05-28 Corixa Corporation Prostate specific fusion protein compositions
CA2281952C (en) 1997-02-25 2011-07-19 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US6943236B2 (en) 1997-02-25 2005-09-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6465611B1 (en) 1997-02-25 2002-10-15 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US6818751B1 (en) 1997-08-01 2004-11-16 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7202342B1 (en) 1999-11-12 2007-04-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6555653B2 (en) * 1997-05-20 2003-04-29 Corixa Corporation Compounds for diagnosis of tuberculosis and methods for their use
AU9689398A (en) * 1997-10-07 1999-04-27 Corixa Corporation Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer
AU2474699A (en) * 1998-01-26 1999-08-09 Genquest Inc. Compositions and methods for detecting and treating prostate cancer
EP1870466A3 (en) * 1998-07-14 2008-03-19 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
US6458925B1 (en) * 1998-08-03 2002-10-01 University Of Maryland, Baltimore Peptide antagonists of zonulin and methods for use of the same
US6387888B1 (en) 1998-09-30 2002-05-14 American Foundation For Biological Research, Inc. Immunotherapy of cancer through expression of truncated tumor or tumor-associated antigen
GB9828840D0 (en) * 1998-12-30 1999-02-17 Univ Nottingham Trent Prostate cancer associated genes and their products
US8143386B2 (en) * 1999-04-07 2012-03-27 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
EP1180151A2 (en) * 1999-05-28 2002-02-20 Sugen, Inc. Protein kinases
KR20010072825A (en) * 1999-06-21 2001-07-31 하빌 이톤 Angiocidin: A Cys-Ser-Val-Thr-Cys-Gly specific tumor cell adhesion receptor
US20020058292A1 (en) * 2000-12-08 2002-05-16 Dillon Davin C. Ovarian tumor antigen and methods of use therefor
CA2386841A1 (en) * 1999-10-07 2001-04-12 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
CA2391369A1 (en) * 1999-11-12 2001-05-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
BR0107643A (en) * 2000-01-14 2003-06-10 Corixa Corp Compositions and processes for prostate cancer therapy and diagnosis
WO2001062893A2 (en) * 2000-02-25 2001-08-30 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
US6541251B1 (en) * 2000-04-26 2003-04-01 The Scripps Research Institute Pancreatic progenitor 1 gene and its uses
PT2133100E (en) * 2000-06-20 2012-01-11 Corixa Corp Mtb32a antigen of mycobacterium tuberculosis with inactivated active site and fusion proteins thereof
WO2002006330A2 (en) * 2000-07-18 2002-01-24 Millennium Pharmaceuticals, Inc. 13237,18480,2245 or 16228 human protein kinase molecules and uses therefor
AU2001279082A1 (en) * 2000-07-31 2002-02-13 Gene Logic, Inc. Expression of gage/page-like protein in benign prostatic hyperplasia
US7048931B1 (en) 2000-11-09 2006-05-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
CA2429749A1 (en) 2000-11-28 2002-06-06 Wyeth Expression analysis of kiaa nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
NZ526707A (en) * 2000-11-28 2005-03-24 Wyeth Corp Use of SMARC nucleic acid and polypeptide expression analysis for the diagnosis and prognosis of prostate cancer
JP2004526425A (en) * 2000-11-28 2004-09-02 ワイス Expression analysis of FKBP nucleic acids and polypeptides useful for diagnosis and treatment of prostate cancer
WO2002068620A2 (en) * 2001-02-26 2002-09-06 Pe Corporation (Ny) Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
EP2295074A1 (en) * 2001-03-07 2011-03-16 Mannkind Corporation Anti-neovasculature preparations for treating cancer
US20030118585A1 (en) * 2001-10-17 2003-06-26 Agy Therapeutics Use of protein biomolecular targets in the treatment and visualization of brain tumors
JP2005505258A (en) 2001-06-21 2005-02-24 イシス・イノベイション・リミテッド ANGE gene in atopy
WO2003008582A1 (en) * 2001-07-19 2003-01-30 The New Industry Research Organization Novel human-origin protein binding to sphingosine kinase 1 and polynucleotide encoding the protein
US8507445B2 (en) * 2001-09-07 2013-08-13 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US7026465B2 (en) 2002-02-15 2006-04-11 Corixa Corporation Fusion proteins of Mycobacterium tuberculosis
DE10217254A1 (en) 2002-04-15 2003-10-23 Proteosys Ag Prevention or treatment of tumors comprises treating eukaryotic cells with an agent that modulates the expression and/or function of proteins synthesized and/or secreted by tumors
US8435507B2 (en) * 2004-08-19 2013-05-07 University Of Maryland Prostate-specific antigen-derived MHC class II restricted peptides and their use in vaccines to treat or prevent prostate cancer
US9957569B2 (en) * 2005-09-12 2018-05-01 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
EP1934363B1 (en) 2005-09-12 2013-03-20 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
ES2459018T3 (en) 2006-02-09 2014-05-07 Alba Therapeutics Corporation Close junction effector formulations
EP2057465A4 (en) * 2006-08-09 2010-04-21 Homestead Clinical Corp SPECIFIC ORGAN PROTEINS AND METHODS OF USE
US20090069247A1 (en) 2006-10-06 2009-03-12 Blake Paterson Use of tight junction antagonists to treat inflammatory bowel disease
WO2008052185A2 (en) 2006-10-26 2008-05-02 Alba Therapeutics Corp Materials and methods for the treatment of celiac disease
CA2668961A1 (en) * 2006-11-08 2008-05-15 The Regents Of The University Of Michigan Spink1 as a prostate cancer marker and uses thereof
US9962424B2 (en) * 2007-04-27 2018-05-08 Lantmännen As-Faktor Ab Use of antisecretory factors (AF) for optimizing cellular uptake
ES2376509T3 (en) * 2007-07-06 2012-03-14 The Regents Of The University Of Michigan REPORTS OF GENES MIPOL 1-ETV1.
EP3018216B1 (en) 2007-07-06 2018-09-12 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
US20090047269A1 (en) 2007-08-16 2009-02-19 The Regents Of The University Of Michigan Metabolomic cancer targets
US20110136683A1 (en) 2008-05-28 2011-06-09 Genomedx Biosciences, Inc. Systems and Methods for Expression-Based Discrimination of Distinct Clinical Disease States in Prostate Cancer
EP2382328A2 (en) 2009-01-09 2011-11-02 The Regents of the University of Michigan Recurrent gene fusions in cancer
US20100311815A1 (en) * 2009-02-23 2010-12-09 The Regents Of The University Of Michigan Mir-101 cancer markers
JP5800817B2 (en) * 2009-09-17 2015-10-28 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Recurrent gene fusion in prostate cancer
EP3336200A1 (en) 2010-11-19 2018-06-20 The Regents Of The University Of Michigan Prostate cancer ncrna and uses thereof
US20130267443A1 (en) 2010-11-19 2013-10-10 The Regents Of The University Of Michigan ncRNA AND USES THEREOF
US8945556B2 (en) 2010-11-19 2015-02-03 The Regents Of The University Of Michigan RAF gene fusions
ES3015226T3 (en) 2012-08-16 2025-04-30 Veracyte Sd Inc Prostate cancer prognosis using biomarkers
US11686731B2 (en) 2015-01-05 2023-06-27 Ian Mills Prostate cancer markers and uses thereof
EP3504348B1 (en) 2016-08-24 2022-12-14 Decipher Biosciences, Inc. Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
WO2018132916A1 (en) 2017-01-20 2018-07-26 Genomedx Biosciences, Inc. Molecular subtyping, prognosis, and treatment of bladder cancer
AU2018230784A1 (en) 2017-03-09 2019-10-10 Decipher Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
CA3062716A1 (en) 2017-05-12 2018-11-15 Decipher Biosciences, Inc. Genetic signatures to predict prostate cancer metastasis and identify tumor agressiveness

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994009820A1 (en) * 1992-11-05 1994-05-11 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen
WO1995004548A1 (en) * 1993-08-11 1995-02-16 Jenner Technologies Prostatic cancer vaccine

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990009446A1 (en) * 1989-02-17 1990-08-23 Plant Genetic Systems N.V. Cutinase

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994009820A1 (en) * 1992-11-05 1994-05-11 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen
WO1995004548A1 (en) * 1993-08-11 1995-02-16 Jenner Technologies Prostatic cancer vaccine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
EL-SHIRBINY A M: "PROSTATIC SPECIFIC ANTIGEN", ADVANCES IN CLINICAL CHEMISTRY, vol. 31, 1994, pages 99 - 133, XP000617158 *

Also Published As

Publication number Publication date
CA2249742A1 (en) 1997-09-18
BR9708082A (en) 1999-07-27
NZ331866A (en) 2000-05-26
CO4600637A1 (en) 1998-05-08
AU2329597A (en) 1997-10-01
KR19990087802A (en) 1999-12-27
US6034218A (en) 2000-03-07
AR006250A1 (en) 1999-08-11
AU728186B2 (en) 2001-01-04
EP0914335A2 (en) 1999-05-12
WO1997033909A2 (en) 1997-09-18
NO984229L (en) 1998-11-13
NO984229D0 (en) 1998-09-14

Similar Documents

Publication Publication Date Title
WO1997033909A3 (en) Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer
WO1998037418A3 (en) Compounds for immunodiagnosis of prostate cancer and methods for their use
WO1998050554A3 (en) Enterococcus faecalis polynucleotides and polypeptides
WO1998037093A3 (en) Compounds for immunotherapy of prostate cancer and methods for their use
WO1998053076A3 (en) Compounds for diagnosis of tuberculosis and methods for their use
WO1999033869A3 (en) Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
WO1999047674A3 (en) Compounds and methods for therapy and diagnosis of lung cancer
EA200101037A1 (en) CONNECTIONS AND METHODS FOR THE TREATMENT AND DIAGNOSTICS OF LUNG CANCER
TW581808B (en) Compounds for immunotherapy of prostate cancer and methods for their use
CA2294516A1 (en) Ikk-.beta. proteins, nucleic acids and methods
MXPA02011656A (en) Nrg 2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods.
WO1997009429A3 (en) Compounds and methods for diagnosis of tuberculosis
WO1997008318A3 (en) Compounds and methods for treatment and diagnosis of prostate cancer
WO2002083070A3 (en) Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
ES2133813T3 (en) LAMININE CHAINS: DIAGNOSIS AND THERAPEUTIC USE.
WO2000060077A3 (en) Compounds for therapy and diagnosis of lung cancer and methods for their use
WO2000037643A3 (en) Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
EP0825260A3 (en) Arginase II
WO1998021343A8 (en) Genes encoding telomerase proteins
WO1997008314A3 (en) Telomere repeat binding factor and diagnostic and therapeutic use thereof
EP1589109A3 (en) VMP-like sequences of pathogenic borrelia
AU2740100A (en) A novel, prostate-specific gene for diagnosis, prognosis and management of prostate cancer
WO1999018210A3 (en) Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer
WO2001049716A3 (en) Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
CA2336261A1 (en) Cyclin e2 genes and proteins

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97194019.3

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI

COP Corrected version of pamphlet

Free format text: PAGE 27,DESCRIPTION,AND PAGES 1/3-3/3,DRAWINGS,REPLACED BY NEW PAGES BEARING THE SAME NUMBER;DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2249742

Country of ref document: CA

Ref document number: 2249742

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 331866

Country of ref document: NZ

Ref document number: PA/a/1998/007497

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1019980707293

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1997916017

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1997916017

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1019980707293

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1997916017

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1019980707293

Country of ref document: KR